GlassScriptPhysician profile
Elena Bond
NPI 1700277100
$3,663.44
in general payments reported to CMS, 2019-2025
12 companies · $1,976 in 2025
The $1,976 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
See the full distribution for Psychiatric/Mental Health (Registered Nurse)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $78.98 · 2023: $733 · 2024: $876 · 2025: $1,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,584.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $962.90 | 2023-2025 | |
| Alkermes, INC. | $558.74 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $481.48 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $358.40 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $334.77 | 2023-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $224.13 | 2023-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $185.14 | 2024-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $167.74 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $129.32 | 2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $121.36 | 2024 | Austedo Xr |
| Inspire Medical Systems, INC. | $119.37 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $20.09 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.